Published in Oncotarget on July 10, 2015
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Int J Mol Sci (2015) 0.90
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget (2015) 0.90
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. Oncotarget (2016) 0.82
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Oncotarget (2015) 0.77
Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature. Blood Res (2016) 0.75
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. Biomed Res Int (2015) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res (2010) 43.51
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res (2009) 7.34
Form and function: the laminin family of heterotrimers. Dev Dyn (2000) 4.38
A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell (1999) 4.25
Deciphering signatures of mutational processes operative in human cancer. Cell Rep (2013) 3.61
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell (2014) 3.41
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun (2014) 3.12
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Genetic aberrations and survival in plasma cell leukemia. Leukemia (2008) 2.69
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet (2013) 2.59
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
Methods for evaluating clustering algorithms for gene expression data using a reference set of functional classes. BMC Bioinformatics (2006) 2.18
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia (2013) 2.04
EXCAVATOR: detecting copy number variants from whole-exome sequencing data. Genome Biol (2013) 1.90
Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am (1999) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Plasma cell leukemia. Report on 17 cases. Arch Intern Med (1974) 1.66
Signalling and survival pathways in multiple myeloma. Eur J Cancer (2006) 1.52
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene (2005) 1.51
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia (2013) 1.51
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica (2010) 1.42
Regulation of beta -catenin transformation by the p300 transcriptional coactivator. Proc Natl Acad Sci U S A (2000) 1.41
Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res (2006) 1.37
Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol Life Sci (2013) 1.30
p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood (1993) 1.25
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun (2015) 1.14
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Plasma cell leukemia. Blood Rev (2011) 1.10
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood (2014) 1.09
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res (2013) 1.09
Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer (2009) 1.00
The FAT epidemic: a gene family frequently mutated across multiple human cancer types. Cell Cycle (2013) 1.00
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia (2011) 0.99
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res (2013) 0.98
Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk Lymphoma (2005) 0.95
Cross-regulation of Wnt signaling and cell adhesion. Differentiation (2004) 0.95
Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma. J Proteome Res (2013) 0.95
Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target. Nucleic Acids Res (2013) 0.93
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol (2012) 0.92
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res (2014) 0.89
Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet (2005) 0.87
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia (2013) 0.87
Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res (2008) 0.86
DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes. Genome Med (2014) 0.86
Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. Dev Immunol (2000) 0.85
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget (2014) 0.82
Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells. Haematologica (2013) 0.80
Cell adhesion to fibronectin down-regulates the expression of Spy1 and contributes to drug resistance in multiple myeloma cells. Int J Hematol (2013) 0.77